Chang Victoria S, Schwartz Stephen G, Davis Janet L, Flynn Harry W
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller, School of Medicine, Miami, FL, USA.
Am J Ophthalmol Case Rep. 2018 Dec 8;13:127-130. doi: 10.1016/j.ajoc.2018.12.003. eCollection 2019 Mar.
To describe an immunosuppressed patient who developed acute-onset postoperative endophthalmitis caused by a moxifloxacin-resistant strain of after cataract surgery despite the use of intracameral moxifloxacin.
A 76-year old woman with a history of birdshot chorioretinopathy controlled on systemic immunosuppression underwent uneventful cataract surgery in her right eye. Compounded intracameral moxifloxacin 0.2 cc of 1mg/0.1mL (Edge Pharmacy, Syracuse, NY) was injected intraoperatively as prophylaxis, and the patient was placed on a standard regimen of trimethoprim-polymyxin b (10000-0.1unit/mL) and prednisolone acetate 1% postoperatively. Four days later, the patient experienced a sudden decrease in vision in the right eye. Anterior chamber inflammation, vitritis, and vasculitis were seen in the operated eye. The patient underwent a vitreous tap and intravitreal injections of vancomycin (1mg/0.1mL), ceftazidime (2.25mg/0.1mL), and dexamethasone (0.4mg/0.1mL). Cultures grew resistant to moxifloxacin (MIC ≥8mg/L). The inflammation resolved over two months. Eight months later, the patient underwent uncomplicated cataract surgery in the left eye. Intracameral antibiotics were not used, however her systemic immunosuppressive therapy was held for several weeks perioperatively. One year after the initial surgeries, the patient had an uncorrected visual acuity of 20/20 in each eye.
, the most common cause of postoperative endophthalmitis, is increasingly resistant to fluoroquinolones. Adequate concentrations of intracameral antibiotics need to be achieved in order to exceed minimal inhibitory concentration values of the targeted pathogen. Although intracameral moxifloxacin has been reported to decrease the rate of endophthalmitis after cataract surgery, it does not eliminate the risk.
描述一名免疫抑制患者,尽管术中使用了前房内注射莫西沙星,但白内障手术后仍因耐莫西沙星菌株发生急性术后眼内炎。
一名76岁女性,有鸟枪弹样视网膜脉络膜炎病史,接受全身免疫抑制治疗病情得到控制,右眼白内障手术顺利。术中注射了0.2cc浓度为1mg/0.1mL的复方前房内莫西沙星(Edge药房,纽约州锡拉丘兹)作为预防措施,术后患者接受了标准方案的甲氧苄啶-多粘菌素b(10000-0.1单位/mL)和1%醋酸泼尼松龙治疗。四天后,患者右眼视力突然下降。手术眼可见前房炎症、玻璃体炎和血管炎。患者接受了玻璃体穿刺及玻璃体内注射万古霉素(1mg/0.1mL)、头孢他啶(2.25mg/0.1mL)和地塞米松(0.4mg/0.1mL)。培养结果显示分离出的菌株对莫西沙星耐药(最低抑菌浓度≥8mg/L)。炎症在两个月内消退。八个月后,患者左眼进行了无并发症的白内障手术。术中未使用前房内抗生素,但围手术期她的全身免疫抑制治疗暂停了几周。初次手术后一年,患者每只眼睛的裸眼视力均为20/20。
术后眼内炎最常见的病因对氟喹诺酮类药物的耐药性日益增加。需要达到足够的前房内抗生素浓度,以超过目标病原体的最低抑菌浓度值。尽管有报道称前房内注射莫西沙星可降低白内障手术后眼内炎的发生率,但并不能消除风险。